Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis

被引:5
|
作者
Yang, Huili [1 ,2 ]
Feng, Lian [1 ,2 ]
Xu, Linyi [1 ,2 ]
Jiang, Dansheng [1 ,2 ]
Zhai, Fenfen [3 ]
Tong, Guangdong [1 ]
Xing, Yufeng [1 ]
机构
[1] Shenzhen Tradit Chinese Med Hosp, Hepatol Dept, Shenzhen 518033, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen 518033, Guangdong, Peoples R China
[3] Shenzhen Futian Ctr Chron Dis Control, Shenzhen 518048, Guangdong, Peoples R China
关键词
APOLIPOPROTEIN-B; PPAR-ALPHA; MICROBIOTA; METABOLISM; PROGRESSION; DEFICIENCY; DISORDERS; BACTERIA; RECEPTOR; OBESITY;
D O I
10.1155/2022/4801695
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with an increasing incidence rate but few therapies. Shugan Xiaozhi decoction (SX) has demonstrated beneficial effects in treating NAFLD with an unclear mechanism. This study was aimed at investigating the therapeutic mechanism of SX on high-fat diet-induced NAFLD rats via the gut-liver axis. Hepatic steatosis and integrity of intestinal mucosa in NAFLD rats were assessed by histopathological staining. The level of lipid and inflammation were estimated by enzyme-linked immunosorbent assay. Western Blotting was used to detect apolipoprotein (apo) B48 expression. 16S rRNA analysis was used to measure the changes of gut microbial composition after SX treatment. The expressions of zona occludens 1 protein (ZO-1), occludin, and secretory immunoglobulin A (sIgA) in the colon were detected by immunostaining to investigate the intestinal barrier function. Our study found that SX reduced hepatic steatosis, the levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, and triglyceride and apoB48 expression but increased peroxisome proliferator activated receptor alpha (PPAR alpha) level. Moreover, SX altered the diversity of gut microbiota, upregulating the relative abundance of f_Prevotellaceae, while downregulating f_Bacteroidales_ S24-7, f_Lachnospiraceae, f_Ruminococcaceae, f_Erysipelotrichaceae, and f_Desulfovibrionaceae. By increasing the expression of ZO-1 and occludin and decreasing the level of proinflammatory factors, including sIgA, lipopolysaccharide, tumor necrosis factor-alpha, interleukin-1 beta, monocyte chemotactic protein-1, and transforming growth factor-beta 1, SX improved intestinal mucosal integrity and barrier function. Our study illustrated that the gut-liver axis was a potential way for SX to ameliorate NAFLD, that is, by regulating the expression of PPAR alpha, apoB48, and modulating gut microbiota to protect the intestinal barrier function, and thus alleviate lipid deposition and inflammatory response in the liver.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Alcoholic liver disease and the gut-liver axis
    Szabo, Gyongyi
    Bala, Shashi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (11) : 1321 - 1329
  • [22] Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation
    Yang, Rong
    Yang, Huili
    Jiang, Dansheng
    Xu, Linyi
    Feng, Lian
    Xing, Yufeng
    PEERJ, 2022, 10
  • [23] Targeting the gut-liver axis in liver disease
    Wiest, Reiner
    Albillos, Agustin
    Trauner, Michael
    Bajaj, Jasmohan S.
    Jalan, Rajiv
    JOURNAL OF HEPATOLOGY, 2017, 67 (05) : 1084 - 1103
  • [24] The gut-liver axis in fatty liver disease: role played by natural products
    Ming, Zhu
    Ruishi, Xie
    Linyi, Xu
    Yonggang, Yang
    Haoming, Luo
    Xintian, Lan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Zhuyu Pill Alleviates Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism through the Gut-Liver Axis
    Xu, Lu
    Xu, Kunhe
    Xiong, Peiyu
    Zhong, Chun
    Zhang, Xiaobo
    Gao, Rui
    Zhou, Xin
    Shen, Tao
    ACS OMEGA, 2023, 8 (32): : 29033 - 29045
  • [26] The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
    Bhardwaj, Monika
    Mazumder, Papiya Mitra
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (11) : 8421 - 8443
  • [27] Gut-liver axis, nutrition, and non-alcoholic fatty liver disease
    Kirpich, Irina A.
    Marsano, Luis S.
    McClain, Craig J.
    CLINICAL BIOCHEMISTRY, 2015, 48 (13-14) : 923 - 930
  • [28] Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
    Poeta, Marco
    Pierri, Luca
    Vajro, Pietro
    CHILDREN-BASEL, 2017, 4 (08):
  • [29] Effects of Bifidobacterium and rosuvastatin on metabolic-associated fatty liver disease via the gut-liver axis
    Ran, Xue
    Wang, Ying-jie
    Li, Shi-gang
    Dai, Chi-bing
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [30] Bacteroides ovatus alleviates high-fat and high-cholesterol-induced nonalcoholic fatty liver disease via gut-liver axis
    Sun, Changrui
    Xiong, Xuan
    Liu, Maoyu
    Liang, Qi
    Zhao, Qian
    Wei, Guocui
    Shi, Jianyou
    Li, Xiuxia
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 142